Phase 1 Study of MKC-1 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions
Advanced Cancer
Interventions
DRUG

MKC-1

30 mg and 100 mg capsules, dosed BID daily on a continuous schedule

Trial Locations (1)

53792

U. of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY

NCT00656461 - Phase 1 Study of MKC-1 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter